TLR8 Agonist VTX-2337

DRUG3 trials

Sponsors

Gynecologic Oncology Group, University of Washington, Mayo Clinic

Conditions

Colorectal AdenocarcinomaMalignant Ovarian Mixed Epithelial TumorMetastatic Pancreatic AdenocarcinomaMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaOvarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous Cystadenocarcinoma

Phase 1

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

CompletedNCT01294293

Gynecologic Oncology GroupMalignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma +7

Start: 2011-03-31Updated: 2014-12-25

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

CompletedNCT01334177

University of WashingtonMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer +38

Start: 2011-06-30Updated: 2015-03-05

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

TerminatedNCT02650635

Mayo ClinicColorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Breast Carcinoma +14

Start: 2016-02-05End: 2017-06-01Updated: 2018-09-05

Related Papers

Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy

Clinical Cancer Research2016-10-0434 citations

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

PLoS ONE2016-02-2966 citations